John R Burnett

List of Publications by Year
in descending order

129 papers	4,602 citations	101543 36 h-index	114465 63 g-index
131 all docs	131 docs citations	131 times ranked	5082 citing authors

#	Article	IF	Citations
1	The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007, 193, 445-448.	0.8	323
2	Phenylketonuria: an inborn error of phenylalanine metabolism. Clinical Biochemist Reviews, 2008, 29, 31-41.	3.3	255
3	HDL Particle Size Is a Critical Determinant of ABCA1-Mediated Macrophage Cellular Cholesterol Export. Circulation Research, 2015, 116, 1133-1142.	4.5	240
4	Lipid Disorders and Mutations in the APOB Gene. Clinical Chemistry, 2004, 50, 1725-1732.	3.2	191
5	Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 2011, 12, 221-263.	1.2	181
6	Vitamin E in Human Health and Disease. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 417-450.	6.1	156
7	Vitamin E and oxidative stress in abetalipoproteinemia and familial hypobetalipoproteinemia. Free Radical Biology and Medicine, 2015, 88, 59-62.	2.9	129
8	Common and Rare ABCA1 Variants Affecting Plasma HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1983-1989.	2.4	117
9	Genetic determinants of hepatic steatosis in man. Journal of Lipid Research, 2011, 52, 593-617.	4.2	115
10	Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 2019, 51, 148-154.	0.6	113
11	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion. Current Opinion in Lipidology, 1997, 8, 138-145.	2.7	95
12	Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2589-2600.	2.4	90
13	Monogenic Hypocholesterolaemic Lipid Disorders and Apolipoprotein B Metabolism. Critical Reviews in Clinical Laboratory Sciences, 2005, 42, 515-545.	6.1	90
14	A Novel Nontruncating APOB Gene Mutation, R463W, Causes Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2003, 278, 13442-13452.	3.4	82
15	Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Journal of Lipid Research, 1999, 40, 1317-1327.	4.2	70
16	Missense Mutations in APOB within the Î²Î±1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia. Journal of Biological Chemistry, 2007, 282, 24270-24283.	3.4	66
17	Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. International Journal of Cardiology, 2015, 201, 633-638.	1.7	66
18	Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience. Atherosclerosis, 2015, 239, 93-100.	0.8	65

#	Article	IF	Citations
19	Lipids, lipoproteins, atherosclerosis and cardiovascular disease. Clinical Biochemist Reviews, 2004, 25, 2.	3.3	63
20	Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis, 2012, 224, 430-434.	0.8	61
21	Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 265-272.	4.1	60
22	Inhibition of the Apical Sodium-Dependent Bile Acid Transporter Reduces LDL Cholesterol and ApoB by Enhanced Plasma Clearance of LDL ApoB. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1884-1891.	2.4	58
23	Contemporary Aspects of the Biology and Therapeutic Regulation of the Microsomal Triglyceride Transfer Protein. Circulation Research, 2015, 116, 193-205.	4.5	58
24	Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Critical Reviews in Clinical Laboratory Sciences, 2011, 48, 1-18.	6.1	57
25	Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects. Journal of the American College of Cardiology, 2014, 63, 2365-2373.	2.8	57
26	MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?. Expert Opinion on Therapeutic Targets, 2007, 11, 181-189.	3.4	54
27	Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Annals of Clinical Biochemistry, 2012, 49, 534-537.	1.6	51
28	Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia. Heart Lung and Circulation, 2021, 30, 324-349.	0.4	51
29	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. Annals of Clinical Biochemistry, 2002, 39, 203-210.	1.6	50
30	The Magnitude of Decrease in Hepatic Very Low Density Lipoprotein Apolipoprotein B Secretion Is Determined by the Extent of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition in Miniature Pigs1. Endocrinology, 1999, 140, 5293-5302.	2.8	48
31	Update on Primary Hypobetalipoproteinemia. Current Atherosclerosis Reports, 2014, 16, 423.	4.8	48
32	Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions. Journal of Clinical Lipidology, 2016, 10, 1329-1337.e3.	1.5	46
33	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opinion on Biological Therapy, 2013, 13, 429-435.	3.1	45
34	Common and rare gene variants affecting plasma LDL cholesterol. Clinical Biochemist Reviews, 2008, 29, 11-26.	3.3	45
35	Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vascular Health and Risk Management, 2012, 8, 651.	2.3	43
36	A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1704-1714.	3.6	41

#	Article	IF	Citations
37	Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2020, 76, 2736-2739.	2.8	39
38	Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 89-137.	6.1	37
39	Clinical utility gene card for: Abetalipoproteinaemia. European Journal of Human Genetics, 2012, 20, 1-3.	2.8	37
40	Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?. Clinical Chemistry, 2019, 65, 1258-1266.	3.2	37
41	Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis. Clinical Cardiology, 2018, 41, 378-384.	1.8	36
42	Liver Dysfunction and Steatosis in Familial Hypobetalipoproteinemia. Clinical Chemistry, 2005, 51, 266-269.	3.2	35
43	The HMG-CoA Reductase Inhibitor Atorvastatin Increases the Fractional Clearance Rate of Postprandial Triglyceride-Rich Lipoproteins in Miniature Pigs. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1906-1914.	2.4	33
44	Acyl coenzyme A: cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Clinica Chimica Acta, 1999, 286, 231-242.	1.1	33
45	Assessment of Tocopherol Metabolism and Oxidative Stress in Familial Hypobetalipoproteinemia. Clinical Chemistry, 2006, 52, 1339-1345.	3.2	31
46	Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 387-403.	4.7	30
47	Postprandial Lipoprotein Metabolism in Familial Hypobetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1474-1478.	3.6	29
48	Ï‰-3 Fatty Acid Ethyl Esters Diminish Postprandial Lipemia in Familial Hypercholesterolemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3732-3739.	3.6	29
49	Tangier disease: update for 2020. Current Opinion in Lipidology, 2020, 31, 80-84.	2.7	29
50	Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. Current Opinion in Molecular Therapeutics, 2009, 11, 681-91.	2.8	29
51	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology, 2016, 12, 467-484.	9.6	28
52	Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. Journal of Lipid Research, 2003, 44, 943-952.	4.2	27
53	Screening for familial hypercholesterolaemia. Pathology, 2012, 44, 122-128.	0.6	27
54	Detecting familial hypercholesterolaemia in the community: Impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis, 2014, 234, 469-472.	0.8	27

#	Article	IF	Citations
55	Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opinion on Investigational Drugs, 2006, 15, 1337-1351.	4.1	25
56	Novel missense MTTP gene mutations causing abetalipoproteinemia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1548-1554.	2.4	24
57	High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency. Atherosclerosis, 2016, 253, 7-14.	0.8	23
58	High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. Annals of Clinical Biochemistry, 2008, 45, 170-176.	1.6	22
59	Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipoprotein B secretion in vivo: effect of dietary fat and cholesterol. Lipids and Lipid Metabolism, 1998, 1393, 63-79.	2.6	21
60	The role of patient registries for rare genetic lipid disorders. Current Opinion in Lipidology, 2018, 29, 156-162.	2.7	20
61	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-553.	1.7	19
62	Protein Kinase C Controls Vesicular Transport and Secretion of Apolipoprotein E from Primary Human Macrophages. Journal of Biological Chemistry, 2013, 288, 5186-5197.	3.4	19
63	The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats. Current Atherosclerosis Reports, 2018, 20, 31.	4.8	19
64	Parentâ€“child genetic testing for familial hypercholesterolaemia in an Australian context. Journal of Paediatrics and Child Health, 2018, 54, 741-747.	0.8	18
65	PCSK9 â€” A Journey to Cardiovascular Outcomes. New England Journal of Medicine, 2018, 379, 2161-2162.	27.0	18
66	Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs, 2012, 21, 1427-1432.	4.1	17
67	Clinical utility gene card for: Familial Hypobetalipoproteinaemia (APOB). European Journal of Human Genetics, 2012, 20, 3-3.	2.8	14
68	Clinical utility gene card for: Sitosterolaemia. European Journal of Human Genetics, 2017, 25, 512-512.	2.8	14
69	Update on the diagnosis, treatment and management of rare genetic lipid disorders. Pathology, 2019, 51, 193-201.	0.6	14
70	An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia. Atherosclerosis, 2020, 298, 52-57.	0.8	14
71	Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry. Heart Lung and Circulation, 2021, 30, 372-379.	0.4	14
72	Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. IDrugs: the Investigational Drugs Journal, 2007, 10, 805-13.	0.7	14

#	Article	IF	Citations
73	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. Clinica Chimica Acta, 2009, 409, 136-139.	1.1	13
74	Clinical features and genetic analysis of three patients with severe hypertriglyceridaemia. Annals of Clinical Biochemistry, 2014, 51, 485-489.	1.6	13
75	The potential role of an expert computer system to augment the opportunistic detection of individuals with familial hypercholesterolaemia from a community laboratory. Clinica Chimica Acta, 2015, 448, 18-21.	1.1	13
76	Interpretative comments specifically suggesting specialist referral increase the detection of familial hypercholesterolaemia. Pathology, 2016, 48, 463-466.	0.6	13
77	Recent developments in the genetics of LDL deficiency. Current Opinion in Lipidology, 2013, 24, 111-115.	2.7	12
78	Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Current Opinion in Molecular Therapeutics, 2006, 8, 461-7.	2.8	12
79	A novel missense HGD gene mutation, K57N, in a patient with alkaptonuria. Clinica Chimica Acta, 2009, 403, 254-256.	1.1	11
80	Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. Clinica Chimica Acta, 2013, 421, 121-125.	1.1	11
81	Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia. Clinica Chimica Acta, 2020, 510, 211-215.	1.1	11
82	Pilot study of universal screening of children and childâ€parent cascade testing for familial hypercholesterolaemia in Australia. Journal of Paediatrics and Child Health, 2022, 58, 281-287.	0.8	11
83	Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a). Atherosclerosis, 2022, 349, 219-226.	0.8	11
84	Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB) â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	10
85	Anacetrapib, a cholesteryl ester transfer protein inhibitor. Expert Opinion on Investigational Drugs, 2012, 21, 103-109.	4.1	9
86	Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy, 2016, 17, 275-281.	1.8	9
87	Familial hypobetalipoproteinaemia: a rare presentation to the lipid clinic. Medical Journal of Australia, 1993, 159, 272-274.	1.7	8
88	The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1738, 10-18.	2.4	8
89	Hypobetalipoproteinaemia secondary to chronic hepatitis C virus infection in a patient with familial hypercholesterolaemia. Annals of Clinical Biochemistry, 2009, 46, 420-422.	1.6	8
90	Clinical utility gene card for: Abetalipoproteinaemia â€“ Update 2014. European Journal of Human Genetics, 2015, 23, 889-889.	2.8	8

#	Article	IF	Citations
91	Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. Current Opinion in Investigational Drugs, 2006, 7, 850-6.	2.3	8
92	Therapeutic considerations for postprandial dyslipidaemia. Diabetes, Obesity and Metabolism, 2001, 3, 143-156.	4.4	7
93	â€œMilkyâ€•urine: a case of chyluria. Medical Journal of Australia, 2004, 180, 89-89.	1.7	7
94	Running interference to lower cholesterol. Lancet, The, 2014, 383, 10-12.	13.7	7
95	Clinical utility gene card for: Tangier disease. European Journal of Human Genetics, 2017, 25, e1-e3.	2.8	7
96	A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment. Clinical Genetics, 2020, 97, 257-263.	2.0	7
97	Eflucimibe. Pierre Fabre/Eli Lilly. Current Opinion in Investigational Drugs, 2003, 4, 347-51.	2.3	7
98	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 182, 552-3.	1.7	7
99	Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1484-E1490.	3.6	6
100	Familial hypobetalipoproteinemia in a Turkish family with hereditary spastic paraplegia. Clinica Chimica Acta, 2008, 390, 152-155.	1.1	5
101	Documenting family history in children with hypercholesterolaemia: A lost opportunity. Journal of Paediatrics and Child Health, 2017, 53, 470-473.	0.8	5
102	Lipids and cardiovascular disease. Pathology, 2019, 51, 129-130.	0.6	5
103	Publication metrics: what do they mean?. Pathology, 2020, 52, 619-620.	0.6	5
104	Lipoprotein apheresis and <scp>PCSK9</scp> inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand. Journal of Clinical Apheresis, 2021, 36, 48-58.	1.3	5
105	Lipoprotein lipase deficiency presenting with neonatal perianal abscesses. BMJ Case Reports, 2016, 2016, bcr2015212587.	0.5	5
106	Câ€•reactive protein: a new cardiovascular risk factor?. Medical Journal of Australia, 2000, 173, 117-118.	1.7	4
107	Finding the Therapeutic Sweet Spot. Circulation: Cardiovascular Genetics, 2015, 8, 637-639.	5.1	4
108	FM-VP4 Forbes Medi-Tech. Current Opinion in Investigational Drugs, 2003, 4, 1120-5.	2.3	4

#	Article	IF	Citations
109	A novel missense SMPD1 gene mutation, T460P, and clinical findings in a patient with Niemannâ€“Pick disease type B presenting to a lipid disorders clinic. Annals of Clinical Biochemistry, 2014, 51, 615-618.	1.6	3
110	Design, development and deployment of a web-based patient registry for rare genetic lipid disorders. Pathology, 2020, 52, 447-452.	0.6	3
111	Avasimibe Pfizer. Current Opinion in Investigational Drugs, 2002, 3, 1328-33.	2.3	3
112	Estimating LDL ApoB: Infomania or Clinical Advance?. Clinical Chemistry, 2008, 54, 782-784.	3.2	2
113	Novel APOB missense variants, A224T and V925L, in a black South African woman with marked hypocholesterolemia. Journal of Clinical Lipidology, 2016, 10, 604-609.	1.5	2
114	Lipoprotein metabolism in an apoB-80 familial hypobetalipoproteinemia heterozygote. Clinical Biochemistry, 2016, 49, 720-722.	1.9	2
115	Publication metrics: it really is all about the numbers. Pathology, 2021, 53, 561-563.	0.6	2
116	Measuring myocardial damage. Medical Journal of Australia, 2001, 174, 163-164.	1.7	1
117	Filiarial chyluria with nephrotic-range proteinuria and associated hypoalbuminaemia and hypogammaglobulinaemia secondary to bilateral lymphorenal fistulae. BMJ Case Reports, 2017, 2017, bcr-2017-221114.	0.5	1
118	Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. Annals of Clinical Biochemistry, 2021, 58, 153-156.	1.6	1
119	l-asparaginase-induced biochemical toxicities in young adults with acute lymphoblastic leukaemia and T-lymphoblastic lymphoma. Pathology, 2021, 53, 924-926.	0.6	1
120	Isolated brachydactyly type E and idiopathic pancreatitis in a patient presenting to a lipid disorders clinic. BMJ Case Reports, 2017, 2017, bcr-2016-218825.	0.5	1
121	Torcetrapib + atorvastatin (Pfizer). Current Opinion in Investigational Drugs, 2005, 6, 944-50.	2.3	1
122	Familial hypercholesterolaemia: a look back, a look ahead. Medical Journal of Australia, 2005, 183, 222-223.	1.7	0
123	New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents, 2006, 16, 349-361.	5.0	0
124	SPG11 mutation in a Turkish familial hypobetalipoproteinemia family with hereditary spastic paraplegia. Clinica Chimica Acta, 2015, 445, 1.	1.1	0
125	Lipoprotein Lipase Deficiency in an Infant With Chylomicronemia, Hepatomegaly, and Lipemia Retinalis. Global Pediatric Health, 2017, 4, 2333794X1771583.	0.7	0
126	The lipid profile in children prior to isotretinoin therapy: an opportunity to detect familial hypercholesterolaemia. Pathology, 2021, 53, 288-290.	0.6	0

#	Article	IF	Citations
127	Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia. Contemporary Endocrinology, 2015, , 251-266.	0.1	0
128	Incidental diagnosis of LPL deficiency in an infant presenting with an acute respiratory infection. Clinica Chimica Acta, 2022, 529, 1-3.	1.1	0
129	Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. IDrugs: the Investigational Drugs Journal, 2006, 9, 495-9.	0.7	0